In 2021, operating income from these PBMs' affiliated pharmacies from specialty generics totaled 12% of all operating income for the parent corporations' business segments. The Big 3 PBMs are ...

The agency’s report found that the “Big 3 PBMs” – CVS Health’s (CVS) Caremark Rx, UnitedHealth’s (UNH) OptumRx, and Cigna’s (CI) Express Scripts – marked up “numerous specialty ...

The "Big 3" PBMs also separately generated an estimated $1.4 billion of income from spread pricing, FTC finds. Jeff Lagasse, Editor A complete guide to lease accounting for healthcare organizations ...

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

The Federal Trade Commission on Jan. 14 published a second interim staff report on the prescription drug middleman industry, ...

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

The report found that these “Big 3” pharmacy benefit managers (PBMs) in the U.S. pocketed about $7.3 billion in excess revenue between 2017 and 2022 by marking up certain medicines by ...

Staff’s latest report found that the ‘Big 3 PBMs’—Caremark Rx, LLC (CVS), Express Scripts, Inc. (ESI), and OptumRx, Inc. (OptumRx)—marked up numerous specialty generic drugs dispensed at ...

The three biggest PBM-owned pharmacies charged ... The new report is a sequel to a report, released in July, that accused big PBMs of paying their own pharmacies more for drugs than they paid ...

During the study period, the affiliated pharmacies of the Big Three PBMs earned more than $7.3 billion in dispensing revenue above their estimated acquisition cost, as determined by the National ...

In fact, a recent report found that 52% of employers are considering changing their PBM in the next 1-3 years. While 72% of employers still primarily contract with a Big Three PBM, 12% have ...

The investigation revealed the three biggest PBMs undertook a variety of actions that boosted their earnings but increased costs for plan sponsors, taxpayers and patients, according to the FTC.